Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human JAK3 Antibodies:
anti-Mouse (Murine) JAK3 Antibodies:
anti-Rat (Rattus) JAK3 Antibodies:
Go to our pre-filtered search.
Human Monoclonal JAK3 Primary Antibody for ICC, FACS - ABIN969224
Lai, Jin, Graham, Witthuhn, Ihle, Liu: A kinase-deficient splice variant of the human JAK3 is expressed in hematopoietic and epithelial cancer cells. in The Journal of biological chemistry 1995
Show all 3 Pubmed References
Human Polyclonal JAK3 Primary Antibody for IF (p), IHC (p) - ABIN742868
Zhang, Liu, Li, Wang, Li, Sun: Jak3 is involved in CCR7-dependent migration and invasion in metastatic squamous cell carcinoma of the head and neck. in Oncology letters 2017
Human Monoclonal JAK3 Primary Antibody for ELISA, FACS - ABIN5581352
Sato, Okano, Tanaka-Kubota, Kimura, Miyamoto, Ono, Yamashita, Mitsuiki, Takagi, Imai, Kajiwara, Ebato, Ogata, Oda, Ohara, Kanegane, Morio: Novel compound heterozygous mutations in a Japanese girl with Janus kinase 3 deficiency. in Pediatrics international : official journal of the Japan Pediatric Society 2016
Human Polyclonal JAK3 Primary Antibody for WB - ABIN658182
Yu, Sun, Feng, Tan, Fang, Zhao, Zhao, Pu, Huang, Xiang, Cao, He: MSX3 Switches Microglia Polarization and Protects from Inflammation-Induced Demyelination. in The Journal of neuroscience : the official journal of the Society for Neuroscience 2015
we report the results of a screening for mutations in SETBP1 (show SETBP1 Antibodies) and JAK3 of a cohort of seventy Italian patients with juvenile myelomonocytic leukemia, identifying 11.4% of them harboring secondary mutations in these two genes and discovering two new mutations in the SKI (show SKI Antibodies) domain of SETBP1 (show SETBP1 Antibodies)
Jak3-mediated phosphorylation of beta-catenin (show CTNNB1 Antibodies) suppressed EGF (show EGF Antibodies)-mediated epithelial-mesenchymal transition and facilitated epithelial barrier functions by AJ localization of phosphorylated beta-catenin (show CTNNB1 Antibodies) through its interactions with alpha-catenin (show CTNNA1 Antibodies).
frequency of JAK3 mutations in the JH2 domain was relatively low in extranodal natural killer/T-cell lymphoma, nasal type (NTCL) in contrast to a previous report; study identified novel JAK3H583Y- and JAK3G589D-activating mutations that were oncogenic and sensitive to a JAK3 inhibitor
In natural killer/T-cell lymphoma (NKTL) as a disease model, phosphorylation of EZH2 (show EZH2 Antibodies) by JAK3 promotes the dissociation of the PRC2 complex leading to decreased global histone H3 (show HIST3H3 Antibodies) lysine 27 methylation levels.
a causal relationship between MLH1 (show MLH1 Antibodies)-deficiency and incidence of oncogenic point mutations in tyrosine kinases driving cell transformation and acquired resistance to kinase-targeted cancer therapies, is reported.
JAK3 mediates smooth muscle cell proliferation and survival during injury-induced vascular remodeling.
Data indicate that phosphorylation of Janus kinase 3 (JAK3) and STAT3 (show STAT3 Antibodies) transcription factor (STAT3 (show STAT3 Antibodies)) was inhibited by latent membrane protein 1 (LMP1 (show PDLIM7 Antibodies))-IgG.
analysis of JAK3 kinetic mechanism and inhibition by tofacitinib
patient had a homozygote of the JAK3 mutation, and her parents were heterozygous carriers.
JAK3 up-regulates SGLT1 (show SLC5A1 Antibodies) activity by increasing the carrier protein abundance in the cell membrane, an effect enforcing cellular glucose uptake into activated lymphocytes and thus contributing to the immune response.
Small-scale in vivo screening identified several genes, including Cd109 (show CD109 Antibodies), that encode novel pro-metastatic factors. We uncovered signaling mediated by Janus kinases (Jaks) and the transcription factor Stat3 (show STAT3 Antibodies) as a critical, pharmacologically targetable effector of CD109 (show CD109 Antibodies)-driven lung cancer metastasis
JAK1 (show JAK1 Antibodies), JAK2 (show JAK2 Antibodies), and JAK3 are involved in stimulation of functional activity of mesenchymal progenitor cells by fibroblast growth factor.
JAK mediated signaling is involved in the differentiation and proliferation of mesenchymal progenitor cells.
This study evaluated a chemical genetic toolkit that evaluated a biphasic requirement for JAK3 kinase activity in IL-2 (show IL2 Antibodies)-driven T cell proliferation.
Experiments implicate JAK1 (show JAK1 Antibodies)/3 signaling in cancer- and myocardial infarction-mediated diaphragm weakness in mice.
Foxp3 (show FOXP3 Antibodies) has a rapid turn over in Treg partly controlled at the transcriptional level by the JAK/STAT (show STAT1 Antibodies) pathway
JAK3 contributes to the regulation of membrane Kv1.5 (show KCNA5 Antibodies) protein abundance and activity, an effect sensitive to ouabain and thus possibly involving Na(+)/K(+) ATPase (show ATP1A1 Antibodies) activity.
JAK3 deficiency is followed by down-regulation of cytosolic Ca(2 (show CA2 Antibodies)+) release, receptor and store operated Ca(2 (show CA2 Antibodies)+) entry and Na(+)/Ca(2 (show CA2 Antibodies)+) exchanger activity in dendritic cells.
Data show that IL-4 (show IL4 Antibodies) induces upregulation of the junction protein claudin-5 (show CLDN5 Antibodies) in endothelial cells (ECs) through activation of Jak/STAT6 (show STAT6 Antibodies) and phosphorylation and translocation of FoxO1 (show FOXO1 Antibodies) from the nucleus to the cytoplasm.
The protein encoded by this gene is a member of the Janus kinase (JAK) family of tyrosine kinases involved in cytokine receptor-mediated intracellular signal transduction. It is predominantly expressed in immune cells and transduces a signal in response to its activation via tyrosine phosphorylation by interleukin receptors. Mutations in this gene are associated with autosomal SCID (severe combined immunodeficiency disease).
Janus kinase 3 (a protein tyrosine kinase, leukocyte)
, leukocyte Janus kinase
, tyrosine-protein kinase JAK3
, Janus kinase 3 protein-tyrosine kinase
, Janus kinase 3, protein-tyrosine kinase
, Janus tyrosine kinase